Clinical Stage Drug Discovery Based on Our Proprietary Platform Technology

SMNH: Delivering Novel Chemistry Solutions for Today's Diseases

SB 9200: A Potential Breakthrough Drug for HBV

Latest News

    • FEBRUARY 15, 2017

    Spring Bank Pharmaceuticals Provides Corporate Update and Reports 2016 Financial and Operational Results

    HOPKINTON, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today provided an update on recent corporate and clinical developments and reported financial results for the fourth quarter and full year ended December 31, 2016.

    “Spring Bank reported a number of significant events in 2016, including financings that generated gross proceeds to us of approximately $32 million; the initiation in June 2016 of our Phase 2a ACHIEVE clinical trial involving our lead product candidate, SB 9200, an orally-available s…

    Read more